Stockscreener 앱 받기
13.63
0.00%
0.01
전일 마감가:
$13.62
열려 있는:
$13.69
하루 거래량:
81,390
Relative Volume:
0.11
시가총액:
$887.69M
수익:
-
순이익/손실:
$-119.67M
주가수익비율:
-4.9927
EPS:
-2.73
순현금흐름:
$-97.30M
1주 성능:
-6.84%
1개월 성능:
+1.04%
6개월 성능:
+33.66%
1년 성능:
-0.37%
1일 변동 폭
$13.43
$13.90
1주일 범위
$13.43
$14.80
52주 변동 폭
$8.241
$18.38
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
명칭
Mineralys Therapeutics Inc
전화
(888) 378-6240
주소
150 N. RADNOR CHESTER ROAD, RADNOR
MLYS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
13.62 | 978.93M | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.08 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.65 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.68 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
570.20 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
292.31 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-11 | 개시 | Jefferies | Hold |
| 2024-07-10 | 개시 | H.C. Wainwright | Buy |
| 2024-04-02 | 개시 | Goldman | Buy |
| 2023-03-07 | 개시 | BofA Securities | Buy |
| 2023-03-07 | 개시 | Credit Suisse | Outperform |
| 2023-03-07 | 개시 | Evercore ISI | Outperform |
| 2023-03-07 | 개시 | Guggenheim | Buy |
| 2023-03-07 | 개시 | Stifel | Buy |
| 2023-03-07 | 개시 | Wells Fargo | Overweight |
모두보기
Mineralys Therapeutics Inc 주식(MLYS)의 최신 뉴스
What analysts say about Mineralys Therapeutics Inc. stockMarket-crushing profits - jammulinksnews.com
Mineralys Therapeutics Inc. Stock Analysis and ForecastConsistently exceptional gains - Autocar Professional
What drives Mineralys Therapeutics Inc. stock priceStrongest growth potential - Autocar Professional
Is Mineralys Therapeutics Inc. a good long term investmentFree Stock Selection - jammulinksnews.com
Mineralys Therapeutics Reports Positive Phase 2 Trial Results for Lorundrostat in Hypertension and CKD - MSN
(MLYS) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Mineralys Therapeutics CFO Adam Levy sells $155k in stock By Investing.com - Investing.com South Africa
Mineralys Therapeutics CEO Congleton sells $230k in shares By Investing.com - Investing.com South Africa
MLYS SEC FilingsMineralys Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Mineralys Therapeutics, Inc. (MLYS) Receives a Hold from Jefferies - The Globe and Mail
Jefferies Initiates Mineralys Therapeutics(MLYS.US) With Hold Rating, Announces Target Price $15 - 富途牛牛
Promising Investment Opportunity in Mineralys Therapeutics Driven by Lorundrostat’s Clinical Success - TipRanks
Jefferies maintains Hold rating on Mineralys stock amid AstraZeneca data By Investing.com - Investing.com South Africa
Jefferies maintains Hold rating on Mineralys stock amid AstraZeneca data - Investing.com Australia
Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat - insights.citeline.com
Mineralys Therapeutics: Navigating Cash Burn and Clinical Triumphs in a $200B Market - AInvest
Mineralys Therapeutics Publishes Phase 3 Trial Results in JAMA for Hypertension Treatment - MSN
Mineralys Therapeutics Reports Positive Topline Data from Phase 2 Explore-CKD Trial of Lorundrostat - MSN
Here's Why We're Watching Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation - Yahoo.co
Verrica Pharmaceuticals Advances Global Phase 3 Trial for YCANTH with Amended Torii Agreement - MyChesCo
Mineralys reports positive phase 3 results for hypertension drug By Investing.com - Investing.com Canada
Mineralys Therapeutics, Inc.(NasdaqGS: MLYS) dropped from Russell 2000 Value Index - MarketScreener
Mineralys’ Drug Significantly Cut Blood Pressure in Key Study - Bloomberg.com
(MLYS) Long Term Investment Analysis - news.stocktradersdaily.com
Is Mineralys Therapeutics, Inc. technically bullish or bearish? - MarketsMojo
Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca - insights.citeline.com
Lorundrostat Shows Clinically Meaningful Outcomes in Patients With CKD and Hypertension - Pharmacy Times
Mineralys stock holds Buy rating at H.C. Wainwright after CKD trial - Investing.com Canada
Mineralys enhances lorundrostat data package ahead of planned NDA - The Pharma Letter
Mineralys Therapeutics (MLYS): Analyst Reiterates Buy Rating and Price Target | MLYS Stock News - GuruFocus
Promising Trial Results for Lorundrostat Boost Mineralys Therapeutics’ Investment Appeal - TipRanks
Mineralys reports positive phase 2 data for lorundrostat in CKD By Investing.com - Investing.com South Africa
Mineralys reports positive phase 2 data for lorundrostat in CKD - Investing.com Australia
Mineralys Therapeutics Shares Climb on Strong Results from Kidney Disease Trial - MSN
Positive Phase II Results for Mineralys Therapeutics’ Lorundrostat Support Buy Rating - TipRanks
Promising Phase 2 Trial Results for Mineralys Therapeutics’ Lorundrostat Support Buy Rating and $42 Price Target - TipRanks
Mineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock Jumps - Benzinga
Transcript : Mineralys Therapeutics, Inc.Special Call - MarketScreener
Mineralys Therapeutics stock jumps after positive kidney disease trial data By Investing.com - Investing.com South Africa
Mineralys Therapeutics Inc (MLYS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Mineralys Therapeutics Inc 주식 (MLYS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Levy Adam Scott | CFO and Secretary |
Jul 11 '25 |
Sale |
14.45 |
10,758 |
155,454 |
206,612 |
| Rodman David Malcom | Chief Medical Officer |
Jul 14 '25 |
Option Exercise |
1.08 |
6,349 |
6,857 |
109,273 |
| Rodman David Malcom | Chief Medical Officer |
Jul 14 '25 |
Sale |
14.59 |
11,366 |
165,879 |
97,907 |
0.12%
0.19%
자본화:
|
볼륨(24시간):